產(chǎn)品名稱

CysLT1 Antagonist Q8

產(chǎn)品貨號(hào)

Axon 2738 CAS [1541762-55-3] MF C17H14ClNO2MW 299.75 Purity: 99% Soluble in DMSO Description CysLT1 antagonist Q8 inhibits developmental angiogenesis in transgenic fluorescent zebrafish, and inhibits human microvascular endothelial cell (HMEC-1) proliferation, tubule formation, and migration. CysLT1 antagonist Q8 elicits antiangiogenic effects in a VEGF-independent in vitro model of angiogenesis and exerts an additive antiangiogenic response with the anti-VEGF biologic bevacizumab. KEYWORDS: CysLT1 Antagonist Q8 | supplier | CysLT1 antagonist | CAS [1541762-55-3] | [1541762-52-0] | Cysteinyl leukotrienes | CysLT | Antagonist | Receptors | Angiogenesis | Antiangiogenic

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

CysLT1 Antagonist Q8

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 2738

CAS [1541762-55-3]

MF C17H14ClNO2
MW 299.75

Purity: 99%
Soluble in DMSO

CysLT1 Antagonist Q8

Description

CysLT1 antagonist Q8 inhibits developmental angiogenesis in transgenic fluorescent zebrafish, and inhibits human microvascular endothelial cell (HMEC-1) proliferation, tubule formation, and migration. CysLT1 antagonist Q8 elicits antiangiogenic effects in a VEGF-independent in vitro model of angiogenesis and exerts an additive antiangiogenic response with the anti-VEGF biologic bevacizumab.

CT Butler et al. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits?Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292(9):3552-3567.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology Pain & Inflammation A5 CysLT

Antagonist of the cysteinyl leukotriene receptor 1 (CysLT1)

Chemical name

(E)-2-(2-(Quinolin-2-yl)vinyl)benzene-1,4-diol hydrochloride

Parent CAS No.

[1541762-52-0]

產(chǎn)品資料